Humphrey Fonge doesn’t just want to create cancer therapeutics – he wants to ensure they make it to the patients who need them.
Fonge and his team at Université Laval have developed a radiotherapeutic which targets Nectin-4, a protein which is over expressed in many cancers including triple-negative breast cancer and non-small cell lung cancer. Targeting this protein allows the therapeutic to attach itself to cancerous cells and treat them. Fonge is now working towards treating patients with this radiotherapeutic in clinical trials.
In Their Own Words is a behind-the-scenes interview series featuring the people who make up the BioCanRx network. We dive into the stories, science, and passion driving Canada’s researchers, highly qualified personnel, and patient advocates as they push the boundaries of cancer immunotherapy—bringing lab discoveries closer to a future when all cancers are curable diseases.
